[Ip-health] EB142: KEI statement on WHO’s decision on the Global strategy and plan of action on public health, innovation and intellectual property

Thiru Balasubramaniam thiru at keionline.org
Fri Jan 26 04:35:21 PST 2018


https://www.keionline.org/23844/



26 January 2018

Geneva

After lengthy negotiations, on Friday, 26 January 2018 the World Health
Organization’s Executive Board approved a decision to reinvigorate the
Organization’s work program on innovation and access to medicines.

Here are two quotes from KEI on the decision:

James Love, Director, Knowledge Ecology International
“The decision has a broad mandate for the WHO to act, and the
recommendations to the member states are very good. We are happy to see
support to expand the medicines patent pool, and that WHO member states
continue to support delinkage of R&D costs from the prices of drugs and
other products. Most surprising to was the opposition from the United
States to measures that would make R&D costs more transparent. When
negotiating drug prices, or designing and evaluating incentives mechanisms
and new business models, having good and granular data on actual R&D costs
is important. Promoting ignorance to protect excessive prices and bad
business models is inexcusable. Ironically, the most important proposals to
make R&D costs transparent have come from the United States, with
bipartisan support. It is somewhat of a mystery why the Trump
Administration has zeroed in on transparency of R&D costs at this meeting,
but it shows that the large drug companies see transparency of R&D costs as
an existential threat to their ability to expand monopolies, protect
excessive prices and protect existing business models.”

Thiru Balasubramaniam, Geneva Representative, Knowledge Ecology
International
“We are heartened that the decision encourages countries to implement
schemes which ‘partially or wholly delink product prices from R&D costs.'”

The text of the decision reads:

The Executive Board, having considered the report by the Director-General
regarding the overall programme review of the global strategy and plan of
action on public health, innovation and intellectual property, and its
annex, decided to recommend to the Seventy-first World Health Assembly the
adoption of the following decision:

The Seventy-first World Health Assembly, having considered the report by
the Director-General regarding the overall programme review of the global
strategy and plan of action on public health, innovation and intellectual
property, and its annex, decided:

(1) to urge Member States to implement, as appropriate, and taking into
account national contexts, the recommendations of the review panel that are
addressed to Member States and consistent with GSPoA.

1 bis. To urge Member States to further discuss the recommendations of the
review panel not emanating from the GSPoA.

(2) to request the Director-General to implement the recommendations
addressed to the WHO Secretariat as prioritized by the review panel, in an
implementation plan, consistent with the GSPoA

(3) to further request the Director-General to submit a report on progress
made in implementing this decision to the Seventy-third World Health
Assembly in 2020, through the Executive Board 146.



-- 
Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org


More information about the Ip-health mailing list